Kōichi Goto

24.2k citations

497 papers · 10.8k indexed · 5 hit papers · h-index 50

Oncology top 0.2%
Pulmonary and Respiratory Medicine top 0.1%
Molecular Biology top 2%
Cancer Research top 0.5%
Epidemiology top 2%

Co-authors: Kiyotaka Yoh Seiji Niho Genichiro Ishii Shingo Matsumoto Yutaka Nishiwaki Hironobu Ohmatsu Yuichiro Ohe Takashi Seto
Topics: Lung Cancer Treatments and Mutations (289 papers)Lung Cancer Research Studies (136 papers)Lung Cancer Diagnosis and Treatment (100 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Journal of Biological Chemistry Nature Communications Nature Genetics
Partner nations: Japan United States South Korea

In The Last Decade

Kōichi Goto

475 papers receiving 10.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

2014 561 citations Takashi Seto, Terufumi Kato et al. profile →
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

2017 308 citations Takashi Seto, Makoto Nishio et al. profile →
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

2020 303 citations Kōichi Goto, Yuichiro Ohe et al. Annals of Oncology profile →
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

2018 225 citations James Chih‐Hsin Yang, Takashi Seto et al. Journal of Clinical Oncology profile →
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Kōichi Goto

Since Specialization

Citations

This map shows the geographic impact of Kōichi Goto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kōichi Goto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kōichi Goto more than expected).

Fields of papers citing papers by Kōichi Goto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kōichi Goto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kōichi Goto. The network helps show where Kōichi Goto may publish in the future.

Co-authorship network of co-authors of Kōichi Goto

This figure shows the co-authorship network connecting the top 25 collaborators of Kōichi Goto. A scholar is included among the top collaborators of Kōichi Goto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kōichi Goto. Kōichi Goto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) 2024 ·Journal of Thoracic Oncology ·Alexander I. Spira,Byoung Chul Cho,Enriqueta Felip,Edward B. Garon,Kōichi Goto,Melissa Johnson,Natasha B. Leighl,Antonio Passaro,David Planchard,Sanjay Popat,James Chih‐Hsin Yang,Xiaoqian Lu,Yong Jiang,(unknown),(unknown),Marcin Kowanetz,Shirley Wang,John T. Le,Jerry Y. Hsu,Caicun Zhou	0
2	1395TiP A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02) 2024 ·Annals of Oncology ·(unknown),Jan C. Brase,Jing Xu,(unknown),Kōichi Goto	2
3	Nurse‐Led Screening‐Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial 2024 ·Cancer Medicine ·Yoshihisa Matsumoto,Shigeki Umemura,(unknown),Daisuke Fujisawa,Takuhiro Yamaguchi,Shunsuke Oyamada,Tempei Miyaji,(unknown),Naoko Kobayashi,Eriko Satomi,(unknown),Tatsuya Morita,Yosuke Uchitomi,Kōichi Goto,Yuichiro Ohe	1
4	515MO Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates 2023 ·Annals of Oncology ·(unknown),(unknown),(unknown),Kōichi Goto,(unknown),(unknown),Athanasios Vasilopoulos,(unknown),(unknown),Wenyin Shi,Vincent Blot,(unknown)	7
5	Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial 2023 ·Lung Cancer ·Tsuneo Shimokawa,Hiroaki Okamoto,Ryunosuke Machida,(unknown),Yukio Hosomi,Yasuto Yoneshima,Hiroshi Tanaka,Kyoichi Okishio,(unknown),Kōichi Goto,Hiroaki Akamatsu,Kaoru Kubota,Kazuhiko Nakagawa,Hidehito Horinouchi,Masahiko Ando,Tomoko Kataoka,Yuichiro Ohe	4
6	510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02) 2023 ·Annals of Oncology ·Yasushi Goto,Kōichi Goto,Toshio Kubo,Kiichiro Ninomiya,S-W. Kim,M-J. Ahn,Kazuhiko Nakagawa,Hidetoshi Hayashi,Junichi Shimizu,Dongwook Kim,(unknown),(unknown),K.H. Lee,(unknown),Kaline Pereira,Ayumi Taguchi,Ahmed Ali,(unknown),(unknown),Pasi A. Jänne	2
7	MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02 2023 ·Journal of Thoracic Oncology ·Pasi A. Jänne,Yasushi Goto,Toshio Kubo,Kiichiro Ninomiya,(unknown),(unknown),Myung‐Ju Ahn,Egbert F. Smit,Adrianus J. de Langen,M. Pérol,(unknown),Silvia Novello,Hidetoshi Hayashi,Junichi Shimizu,D.-W. Kim,(unknown),Fang Cheng,Ayumi Taguchi,Yun Cheng,Kōichi Goto	2
8	1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088 2023 ·Annals of Oncology ·Herbert H. Loong,Gennaro Daniele,(unknown),Ticiana Leal,Kōichi Goto,Yuki Shinno,Kazumi Nishino,Tomohiro Sakamoto,Enriqueta Felip,J.C. Ruffinelli,(unknown),Zhou Wang,Chen Chen,Barbara J. Brennan,(unknown),Martin Kornacker,Paolo Grassi,Xiuning Le,Daniel Shao-Weng Tan,(unknown)	4
9	1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Alison M. Schram,Kōichi Goto,Dongwook Kim,Antoine Hollebecque,Sun Young Rha,Kazumi Nishino,M. Duruisseaux,(unknown),Joon Oh Park,Natasha B. Leighl,Teresa Macarulla,Stephen V. Liu,Mohammed Najeeb Al Hallak,James M. Cleary,Cindy Neuzillet,Yasushi Goto,Andrew K. Joe,(unknown),(unknown),Alexander Drilon	10
10	Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial 2023 ·Cancer Science ·Tatsuya Yoshida,Toru Kumagai,Ryo Toyozawa,Ryohei Katayama,Makoto Nishio,Takashi Seto,Kōichi Goto,Nobuyuki Yamamoto,Yuichiro Ohe,Kentarou Kudou,(unknown),Pingkuan Zhang,Kazuhiko Nakagawa	7
11	Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience 2023 ·Proceedings of the Japan Academy Series B ·Atsushi Ohtsu,Kōichi Goto,Takayuki Yoshino	3
12	Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trialbreakdown → 2022 ·Journal of Clinical Oncology ·Alexander Drilon,Vivek Subbiah,Oliver Gautschi,Pascale Tomasini,Filippo de Braud,Benjamin Solomon,Daniel S.W. Tan,Guzmán Alonso,Jürgen Wolf,Keunchil Park,Kōichi Goto,Victoria Soldatenkova,(unknown),Scott Barker,Tarun Puri,Aimee Bence Lin,Herbert H. Loong,Benjamin Besse	119
13	Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy 2022 ·Cancer Science ·(unknown),Tomoyuki Naito,Hibiki Udagawa,Kōichi Goto,Taichi Miyawaki,Nobuaki Mamesaya,(unknown),Hirotsugu Kenmotsu,Tadasuke Shimokawaji,Terufumi Kato,Taiki Hakozaki,Yusuke Okuma,Masaki Nakamura,Yuko Nakayama,Hirokazu Watanabe,Masahiko Kusumoto,Yuichiro Ohe,Hidehito Horinouchi	6
14	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer 2021 ·Cancer Research ·Yukie Kashima,(unknown),Ayako Suzuki,(unknown),Ikei S. Kobayashi,(unknown),Hibiki Udagawa,Hiroki Izumi,Yuji Shibata,Kosuke Tanaka,Masanori Fujii,Akihiro Ohashi,Masahide Seki,Kōichi Goto,Katsuya Tsuchihara,Yutaka Suzuki,Susumu Kobayashi	49
15	Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression 2020 ·Clinical Cancer Research ·Azusa Tanimoto,Shingo Matsumoto,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Akihiro Nishiyama,Kiyotaka Yoh,Takaya Ikeda,Naoki Furuya,Kazumi Nishino,Yuichiro Ohe,Kōichi Goto,Seiji Yano	38
16	TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations 2019 ·Molecular Cancer Research ·Hibiki Udagawa,(unknown),Akihiro Ohashi,(unknown),(unknown),(unknown),Naomi Abe,(unknown),(unknown),(unknown),(unknown),Akihiro Hashimoto,Kaoru Funabashi,Hiroyuki Yasuda,Kazutaka Miyadera,Kōichi Goto,Daniel B. Costa,Susumu Kobayashi	55
17	Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma 2018 ·Cancer Research ·Hideki Makinoshima,Shigeki Umemura,Ayako Suzuki,Hiroki Nakanishi,Ami Maruyama,Hibiki Udagawa,Sachiyo Mimaki,Shingo Matsumoto,Seiji Niho,Genichiro Ishii,Masahiro Tsuboi,Atsushi Ochiai,Hiroyasu Esumi,Takehiko Sasaki,Kōichi Goto,Katsuya Tsuchihara	33
18	Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors 2017 ·Cancer Research ·Shigenari Nukaga,Hiroyuki Yasuda,Katsuya Tsuchihara,Junko Hamamoto,Keita Masuzawa,Ichiro Kawada,Katsuhiko Naoki,Shingo Matsumoto,Sachiyo Mimaki,Shinnosuke Ikemura,Kōichi Goto,Tomoko Betsuyaku,Kenzo Soejima	131
19	Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung 2016 ·Clinical Cancer Research ·Tomohiro Miyoshi,Shigeki Umemura,Yuki Matsumura,Sachiyo Mimaki,Satoshi Tada,Hideki Makinoshima,Genichiro Ishii,Hibiki Udagawa,Shingo Matsumoto,Kiyotaka Yoh,Seiji Niho,Hironobu Ohmatsu,Keiju Aokage,Tomoyuki Hishida,Junji Yoshida,Kanji Nagai,Kōichi Goto,Masahiro Tsuboi,Katsuya Tsuchihara	139
20	Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation 2014 ·Clinical Cancer Research ·Tatsuya Yoshida,Genichiro Ishii,Kōichi Goto,Shinya Neri,Hiroko Hashimoto,Kiyotaka Yoh,Seiji Niho,Shigeki Umemura,Shingo Matsumoto,Hironobu Ohmatsu,Shinsuke Iida,Akio Niimi,Kanji Nagai,Yuichiro Ohe,Atsushi Ochiai	102

About Kōichi Goto

Kōichi Goto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 497 papers that have together received 10.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (289 papers), Lung Cancer Research Studies (136 papers) and Lung Cancer Diagnosis and Treatment (100 papers). The work is most often cited by research in Oncology (6.6k citations), Pulmonary and Respiratory Medicine (6.4k citations) and Cancer Research (1.9k citations). Kōichi Goto has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Kiyotaka Yoh, Seiji Niho, Genichiro Ishii, Shingo Matsumoto, Yutaka Nishiwaki, Hironobu Ohmatsu, Yuichiro Ohe, Takashi Seto, Nobuyuki Yamamoto and Makoto Nishio. Their work appears in journals such as Journal of Biological Chemistry, Nature Communications and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact